NCT01563913View on ClinicalTrials.gov

Reducing Dyskinesia in Parkinson's Disease With Omega-3 Fatty Acids

PHASE1CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

June 30, 2016

Study Completion Date

June 30, 2016

Conditions
Parkinson's Disease
Interventions
DRUG

Docosahexaenoic Acid (DHA)

Docosahexaenoic Acid (DHA) 2 grams per day taken for 1.5 years

DRUG

Placebo

Sugar Pill, taken for 1.5 years

Trial Locations (1)

97239

VA Portland Health Care System, Portland, OR, Portland

All Listed Sponsors
collaborator

Oregon Health and Science University

OTHER

lead

VA Office of Research and Development

FED

NCT01563913 - Reducing Dyskinesia in Parkinson's Disease With Omega-3 Fatty Acids | Biotech Hunter | Biotech Hunter